Medtronic’s planned acquisition of SPR Therapeutics for $650 million signals a clear strategic direction: expanding earlier-stage, minimally invasive pain management solutions within the rapidly evolving neuromodulation market.
Key highlights from the transaction:
· Deal value: Medtronic will acquire all outstanding equity of SPR Therapeutics in an all-cash transaction valued at $650 million.
· Strategic fit: The acquisition strengthens Medtronic’s neuromodulation portfolio by adding SPR’s temporary peripheral nerve stimulation (PNS) technology, creating broader treatment pathways for chronic pain patients.
· Technology differentiation: SPR’s FDA-cleared Sprint PNS system offers a non-permanent approach to pain management. Instead of a permanent implant, a small lead is placed near the target nerve for treatment periods of up to 60 days.
· Commercial traction: By the end of 2025, SPR Therapeutics reported more than 50,000 Sprint implants, highlighting growing physician adoption and patient acceptance.
· Market opportunity: Chronic pain impacts nearly 50 million people in the U.S., making it one of the largest and most underserved healthcare segments globally. Demand for non-opioid, less invasive treatment options continue to accelerate.
This also marks Medtronic’s third major acquisition in 2026, following:
· Scientia Vascular ($550M)
· CathWorks (up to $585M)
Collectively, these moves reflect a broader MedTech trend:
· Companies are prioritizing high-growth, technology-enabled therapies that improve patient outcomes while expanding intervention earlier in the care continuum.
The SPR acquisition positions Medtronic to compete more aggressively in the fast-growing pain management and neuromodulation space, where innovation, minimally invasive care, and long-term patient outcomes are becoming critical differentiators. Medtronic expects to close the deal by the first half of FY2027.